INV 1120
Alternative Names: INV-1120Latest Information Update: 28 Jul 2023
At a glance
- Originator Shenzhen Ionova Life Sciences Co., Ltd.
- Class Antineoplastics; Small molecules
- Mechanism of Action Prostaglandin E EP4 receptor antagonists
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Phase I Solid tumours
Most Recent Events
- 28 Jul 2023 No recent reports of development identified for phase-I development in Solid-tumours(Late-stage disease) in USA (PO)
- 02 Jun 2023 Phase-I clinical trials in Solid tumours (Late-stage disease) in China (PO) before June 2023 (ChiCTR20211872)
- 02 Jun 2023 Efficacy, adverse events and pharmacokinetics data from a phase I trial in solid tumours presented at the 59th Annual Meeting of the American Society of Clinical Oncology (ASCO-2023)